Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 13, 2005
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mysteryKatia Boven, John Knight, Fred Bader, et al.
Antiviral Therapy|September 7, 2012
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological responseJohan Vingerhoets, Laurence Rimsky, Veerle Van Eygen, et al.
Antiviral Therapy|May 30, 2013
96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trialsLaurence Rimsky, Veerle Van Eygen, Annemie Hoogstoel, et al.
AIDS Reviews|May 18, 2013
Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirineHerta Crauwels, Rolf P G van Heeswijk, Marita Stevens, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 10, 2011
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysisLaurence Rimsky, Johan Vingerhoets, Veerle Van Eygen, et al.
Journal of Clinical Pharmacology|May 31, 2013
Impact of food and different meal types on the pharmacokinetics of rilpivirineHerta M Crauwels, Rolf P G van Heeswijk, Annemie Buelens, et al.
Kidney International|May 11, 2005
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringesKatia Boven, Scott Stryker, John Knight, et al.
Antiviral Therapy|January 17, 2014
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)David A Wohl, Chloe Orkin, Manuela Doroana, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2009
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1Hilde Azijn, Ilse Tirry, Johan Vingerhoets, et al.
AIDS Research and Human Retroviruses|September 10, 2011
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trialAimee Wilkin, Anton L Pozniak, Javier Morales-Ramirez, et al.
Pageof 2